Evolent Health Q1 2026 slides: revenue misses forecast, leverage rises

Evolent Health reported Q1 2026 revenue of $496.2 million, missing the $534.0 million consensus by about 7%, though EPS of -$0.02 beat expectations for a -$0.05 loss. Medical Expense Ratio deteriorated sharply to 93.3% from 84.0%, and net debt rose to $791.9 million with leverage increasing to 5.8x LTM Adjusted EBITDA. Management kept full-year 2026 guidance intact at $2.4 billion-$2.6 billion revenue and $110 million-$140 million Adjusted EBITDA despite the weak top-line print.

Analysis

EVH’s print reads less like a one-quarter miss and more like a balance-sheet stress test. The key second-order issue is that management is trying to re-rate the business through pricing while utilization and mix are moving against them; if claims trend stays elevated, higher PMPMs can simply preserve revenue while compressing conversion to cash. That is the dangerous setup for a levered services model: the market may initially reward “beating EPS,” but as soon as investors focus on sustained EBITDA quality and covenant headroom, the multiple can de-rate faster than operating results improve.

The strategic shift away from direct care delivery is directionally right, but the transition window is messy. Selling the lower-ROI asset removes revenue and working capital drag, yet it also strips out a stabilizing earnings stream just as the remaining platform is proving more volatile than expected. The more non-obvious implication is that competitors with better risk pools or more diversified payer exposure can use this period to lock in contracts from health plans looking for margin relief without absorbing as much claims noise.

Catalyst-wise, the next 1-2 quarters matter much more than the full-year guide. If the company cannot show sequential improvement in MER and operating cash flow by midyear, the market will start pricing refinancing risk rather than growth optionality; with leverage near the upper end of what equity investors tolerate, that can tighten the stock’s reaction function to any downside surprise. The contrarian bull case is that a few favorable reserve updates and new contract ramps could make Q3/Q4 look much cleaner than Q1, but that requires proof, not narrative.

Key Decisions for Investors

• Avoid initiating fresh longs in EVH at current levels; treat the post-earnings bounce as tactical only until Q2 claims trend and cash flow confirm a real inflection.
• For existing holders, hedge downside with near-dated put spreads on EVH into the next print; the stock is likely to trade on leverage and MER sensitivity, not just revenue growth.
• Pair trade: long a lower-leverage healthcare services or managed-care winner versus short EVH for 1-3 months; the relative-value edge is the balance-sheet gap, not just operating performance.
• If forced to express a bullish view, wait for a pullback and buy only after management shows two consecutive quarters of improving EBITDA margin and stable net debt; otherwise the risk/reward remains skewed to the downside.